VTGN News and Press, VistaGen Therapeutics Inc. From 02/13/24

2024-02-13 18:34:02 ET Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Conference Call February 13, 2024, 05:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief...

2024-02-13 17:04:03 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaG...

2024-02-13 16:33:22 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaG...

Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical com...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

2024-02-12 17:35:56 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Vistagen climbs as Stifel launches at Buy on anxiety prospects Seeking Alpha’s Quant Rati...

2024-02-12 17:35:43 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Upstart Holdings ( UPST ) STAG Industrial ( STAG ) American International Group ( AIG ) Zillow Group ( Z ) Read the full article on Seeking Alp...

2024-02-07 07:38:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opport...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast to report results for its fiscal year 2024 third quarter end...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5...